<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961829</url>
  </required_header>
  <id_info>
    <org_study_id>SPARC-7</org_study_id>
    <nct_id>NCT02961829</nct_id>
  </id_info>
  <brief_title>Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure</brief_title>
  <official_title>Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is becoming clear that a combination of interventions will be desirable to achieve HIV
      cure. Therefore the investigators propose a pilot proof of concept study, using combination
      of a number of different interventions for eradicating residual plasma viremia and decreasing
      HIV reservoirs. The investigators hypothesize that, (i) antiretroviral intensification using
      Maraviroc, and/or dolutegravir with (ii) Dendritic Cell vaccination using autologous HIV, and
      (iii) purging intervention using the Class III HDACs, Sirtuin-1, and (iv) decreasing the
      ratio of long-lived central memory (TCM)/transitional memory (TTM) CD4+ T-cells using
      Auranofin will provide a synergistic impact leading to a sterilizing cure of HIV infection.
      Results of this study may provide insightful evidence for planning the next steps using the
      more efficacious combination of intervention strategies towards HIV sterilizing cure.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ultrasensitive RNA Viral load,</measure>
    <time_frame>from baseline and every 4 weeks up to 48 weeks.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cell-associated HIV RNA</measure>
    <time_frame>from baseline and every 4 weeks up to 48 weeks.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Episomal DNA</measure>
    <time_frame>from baseline and every 4 weeks up to 48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>specific HIV antibodies</measure>
    <time_frame>from baseline and every 4 weeks up to 48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CD38 and HLA-DR on CD4 and CD8+ cells</measure>
    <time_frame>from baseline and every 4 weeks up to 48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PBMC for env sequence evolution</measure>
    <time_frame>from baseline and every 4 weeks up to 48 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Chronic Infection</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Antiretroviral Treated (ART) Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Five patients will receive no further intervention this group (control group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ART Intensification Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ART Intensification + Nicotinamide Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five patients will receive antiretroviral intensification with maraviroc and dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ART Intensification + Auranofin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks and the gold salt auranofin for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ART Intensification + DC vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five patients will receive antiretroviral intensification with dolutegravir and for 48 weeks, and dendritic cell vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi Interventional Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five patients will receive antiretroviral intensification with dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks, and gold salt for 24 weeks and dendritic cell vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>antiretroviral intensification</description>
    <arm_group_label>ART Intensification Group</arm_group_label>
    <arm_group_label>ART Intensification + Nicotinamide Group</arm_group_label>
    <arm_group_label>ART Intensification + Auranofin Group</arm_group_label>
    <other_name>Selzentry</other_name>
    <other_name>Celsentri</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir</intervention_name>
    <description>antiretroviral intensification</description>
    <arm_group_label>ART Intensification Group</arm_group_label>
    <arm_group_label>ART Intensification + Nicotinamide Group</arm_group_label>
    <arm_group_label>ART Intensification + Auranofin Group</arm_group_label>
    <arm_group_label>ART Intensification + DC vaccine Group</arm_group_label>
    <arm_group_label>Multi Interventional Group</arm_group_label>
    <other_name>Tivicay</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dendritic Cell Vaccine</intervention_name>
    <description>Therapeutic vaccination</description>
    <arm_group_label>ART Intensification + DC vaccine Group</arm_group_label>
    <arm_group_label>Multi Interventional Group</arm_group_label>
    <other_name>DC Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Auranofin</intervention_name>
    <description>purging</description>
    <arm_group_label>ART Intensification + Auranofin Group</arm_group_label>
    <arm_group_label>Multi Interventional Group</arm_group_label>
    <other_name>Gold Salt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirtuin Histone deacetylase inhibitor</intervention_name>
    <description>latency disruption</description>
    <arm_group_label>ART Intensification + Nicotinamide Group</arm_group_label>
    <arm_group_label>Multi Interventional Group</arm_group_label>
    <other_name>Nicotinamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years old Documented HIV-1 infection.

          -  Has voluntarily signed ICF.

          -  On HAART ≥ 2 years, without changes in the 24 weeks immediately prior to screening.

          -  HIV viral load &lt;50 copies/mL, and never &gt; 50 copies/mL on 2 consecutive occasions in
             the last 2 years. CD4 count nadir.

          -  &gt; 350 cells/ mm3 Current CD4 count &gt; 500 cells/ mm3.

          -  R5 HIV-1 at Screening as defined by proviral DNA genotropism.

        Exclusion Criteria:

        A subject will NOT be eligible for study participation if he/she meets ANY of the following
        criteria:

          -  Any evidence of an active AIDS-defining condition.

          -  Any significant acute medical illness in the past 8 weeks.

          -  Women who are pregnant or breastfeeding.

          -  Use of any of the following within 90 days prior to entry: systemic cytotoxic
             chemotherapy; investigational agents; immunomodulators (colony-stimulating factors,
             growth factors, systemic corticosteroids, HIV vaccines, immune globulin, interleukins,
             interferons); coumadin, warfarin, or other Coumadin derivative anticoagulants. Use of
             an agent definitely or possibly associated with effects on QT intervals: amiodarone,
             arsenic trioxide, astemizole, bepridil, chloroquine, chlorpromazine, cisapride,
             clarithromycin, disopyramide, dofetilide, domperidone, droperidol, erythromycin,
             halofantrine, haloperidol, ibutilide, levomethadyl, mesoridazine, methadone,
             pentamidine, pimozide, probucol, procainamide, quinidine, sotalol, sparfloxacin,
             terfenadine, thioridazine.

          -  Receipt of compounds with HDAC inhibitor-like activity, such as valproic acid or
             nicotinamide within the last 30 days. Potential participants may enroll after a 30-day
             washout period.

          -  Known hypersensitivity to the components of gold salt, nicotinamide or its analogs.

          -  Hepatitis B (HBsAg +) or Hepatitis C (HCV RNA +) infection.

          -  Known renal insufficiency defined as calculated creatinine clearance (Cockcroft Gault
             formula) &lt;60 mL/min.

          -  Subjects with a laboratory abnormality grade 3 or 4 with the following exceptions:
             pancreatic amylase, cholesterol, triglyceride, gamma glutamyl transpeptidase,
             bilirubin.

          -  Any condition which, in the investigators opinion, could compromise the subject's
             safety or adherence to the trial protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CCDI</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04040002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Ricardo Sobhie Diaz, MD, PHD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Dendritic Cell vaccination using</keyword>
  <keyword>antiretroviral intensification</keyword>
  <keyword>Auranofin</keyword>
  <keyword>Histone Deacetylase Inhibitor</keyword>
  <keyword>residual viral replication</keyword>
  <keyword>HIV sanctuaries</keyword>
  <keyword>HIV latency</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
    <mesh_term>Auranofin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

